Steve Clark

Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.
Aptose Biosciences Inc (NASDAQ:APTO)

New High for Aptose Biosciences Inc (NASDAQ:APTO)

Aptose Biosciences Inc (NASDAQ:APTO)

Aptose Biosciences Inc (NASDAQ:APTO) shares have hit a new 52-week high, are up over 17%, and trading around the $2 handle in mid-afternoon trading. Volume is heavy for the biotech’s shares as they are trading about seven times their daily average.

Aptose Biosciences Inc (NASDAQ:APTO)

Aptose Biosciences Inc (NASDAQ:APTO) is scheduled to be releasing their Q3 2017 earnings report tomorrow, November 14, 2017, after the close of trading. According to Zacks Investment Research, the consensus of analysts are expecting an EPS loss of (-$0.13) per share.

Canadian-based Aptose Biosciences Inc (NASDAQ:APTO) is a clinical-stage biotechnology company committed that develops personalized therapies designed to address unmet medical needs in cancer patients. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer treatment. The company’s pipeline of small molecule cancer therapeutics includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

APTO Stock Performance

Shareholders of Aptose Biosciences Inc (NASDAQ:APTO) have experienced a good year. Year-to-date, APTO stock is up over 22%, and for the year the gain is an even more impressive 65%. Analysts have given APTO stock a consensus, one-year price target of $3.15. The stock’s 52-week low was established last April at a price of $0.78. Today’s price action, should it hold, will establish a new 52-week high – besting the old mark of $1.79. Given the strong upward momentum of the stock, it is not surprising that the shares have a Relative Strength score of 77 – a level that most traders consider to be a sign of an “overbought” condition.

Aptose Biosciences Inc (NASDAQ:APTO) has no reported sales. Accordingly, their earnings have been negative since 2012. In the past three years, the per share losses have expanded. In 2014 the per share loss was (-$0.53), followed the next year by (-$0.97), and (-$1.15) for 2016.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $APTO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Biostar Pharmaceuticals Inc (NASDAQ:BSPM) Attempts a Close above $2

Biostar Pharmaceuticals Inc (NASDAQ:BSPM)

Biostar Pharmaceuticals Inc (NASDAQ:BSPM) stock is up over 20% and trading above a key $2 resistance level. Volume is heavy – nearly 30 times the listed daily average. No news has come out on the drug manufacturer, but observers are speculating that the market may be jumping in ahead of the company’s earnings release on November 20, 2017.

Biostar Pharmaceuticals Inc (NASDAQ:BSPM)

Biostar Pharmaceuticals Inc (NASDAQ:BSPM), headquartered in China, through its wholly owned subsidiary and controlled affiliates, develops, manufactures, and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company’s most popular product is its XinAoxingOleanolic Acid Capsule, an over-the-counter medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population.

Biostar’s Business

The company has a current ratio of 1.3, which indicates it will be able to satisfy any debt obligations in the near term. While its cash/share figure is only $0.07, it has a book/share value of $14.43. According to reports, industry analysts are expecting Biostar Pharmaceuticals Inc (NASDAQ:BSPM) earnings to grow almost 80% this year.

Sales have taken a hit since 2014 when the company posted a figure of $61.4 million. That year represented the end of an uptrend in its sales. In 2015 the company reported sales of $27.1 million, and just $2.4 million for 2016.

BSPM Stock Performance

Over the past year, BSPM has lost over 50% of its value. In 2016, the stock struggled to remain over the $5 handle and any gains over that price quickly met with selling action. However, in the past quarter BSPM stock has gained around 20%. Further, analysts have a consensus, one-year price target of $7 on the shares. Currently, BSPM stock is trading 70% above its 52-week low of $1.18, but well below its 52-week high of $4.30.

Earnings have been disappointing for long-term holders of the shares. In 2015, the company posted a per share loss of ($11.36, but last year that shrank to (-$2.48). Dilution has been noticeable, but not cringe-worthy. In 2013 there were 1.37 million shares outstanding. But by 2016 the number was listed at 2.3 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $BSPM and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Capricor Therapeutics Inc (NASDAQ:CAPR)

Traders Loving Capricor Therapeutics Inc (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR) shares gapped up this morning and have gained over 20% from their Friday closing price on ten times their average daily volume. CAPR stock opened at $2.65, $0.38 above Friday’s close, and moved above the $3 handle within ten minutes. Sellers then came in and pushed the price down to $2.80 before the shares resumed their upward move. At the time of the writing, 10:15 AM EST, CAPR stock is trading around the $3 once again.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company discovers, develops, and commercializes biological therapeutics for the treatment of rare disorders. Capricor’s lead drug candidate is, CAP-1002 – an “off-the-shelf” cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor is also investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

On November 8, 2017, Beverly Hills, CA-based Capricor Therapeutics, Inc. (NASDAQ:CAPR) reported a Q3 2017 loss of (-$2.7). or (-$0.12) per share, on adjusted revenues of $313,000. The loss beat analyst expectations that forecasted a loss of (-$0.19) per share. The biotech firm also bested expectations in Q2 when actual earnings beat estimates by 11%.

CAPR Stock Performance

At the beginning of 2012 CAPR stock was trading above $20 before it went into a steady slide. Over the past year CAPR stock has experienced a wide range in its price. Its 52-week low is $0.63 but its 52-week high is $4.25.

Shareholders of Capricor Therapeutics, Inc. (NASDAQ:CAPR) have lagged the market as the stock is down 7% year-to-date. However, in the past quarter, shares have risen over 114%. That strong gain is reflected in CAPR’s Relative Strength Index score of 68 – just below the level of 70 which many traders believe to be the threshold figure for an “oversold” condition.

Losses have plagued the company since 2012 when they posted a EPS of (-$0.21), followed by annual EPS losses of (-$0.85), (-$0.53), (-$0.81), and, for 2016, (-$1.01). Sales were on a positive slope from 2013 when it reported a figure of $500,000. By 2015 that number grew to $5.5 million, but declined in 2016 to $4 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CAPR and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Avid Technology, Inc. (NASDAQ:AVID)

Avid Technology, Inc. (NASDAQ:AVID) Q3 Earnings Beat Estimates

Avid Technology, Inc. (NASDAQ:AVID)

Shares of Avid Technology, Inc. (NASDAQ:AVID) gained 26.24% after the global media technology company reported better than expected Q3 2017 financial results. Revenues and bookings exceeded guidance in the quarter. Strong improvement in adjusted EBITDA allowed the company to post a fourth consecutive quarter of positive cash flow.

Avid Technology, Inc. (NASDAQ:AVID)

AVID Investors Reaction

Investors reacted to the stellar financial results by pushing the stock from this year’s lows to $5.10 a share. The stock is up by more than 10% for the year. Avid Technology, Inc. (NASDAQ:AVID) faces resistance at the $5.50 mark above which it could make a to this year’s highs of $6 a share.

Renewed investor interest in the stock is as a result of the company exceeding guidance in all its key metrics. According to Chief Executive Officer, Louis Hernandez, Jr., completion of transformation should allow Avid technology to drive profitable growth as well as increase revenue visibility and cash flow.

AVID Q3 Results

For the three months ended September 30, 2017, Avid technology bookings came above the upper end of guidance at $102.8 million. Constant currency bookings totaled $107.9 million which were in line with guidance. GAAP Revenue was $105.3 million above the upper end of guidance. Gross margin came in at 57.3%.

Net income in the quarter came in at $72,000 as adjusted free cash flow came in at $0.5 million at the upper end of the guidance. Adjusted free cash flow for the first nine months rose to $55.7 million,

According to the Chief Executive Officer, customers ranging from the largest media enterprise continue to adopt Avid Technology, Inc. (NASDAQ:AVID)’s innovative solutions.

“With our cloud-enabling MediaCentral platform, enterprises are unlocking greater strategic value from their Avid partnership as we help them to achieve new economies of scale while they work to engage audiences on any device with increasing amounts of content,” said Mr. Hernandez.

Q4 Outlook

During the quarter, Avid Technology, Inc. (NASDAQ:AVID) signed several multi-year enterprise deals with large customers, including Viacom and NHK. Total licenses for the MediaCentral platform increased 27% year-over-year to 51,000. Direct digital bookings with individual creative professionals increased 35% year-over-year.

For the fourth quarter Avid Technology, Inc. (NASDAQ:AVID) expects bookings to range between $118 and $132 million. Revenue, on the other hand, should range between $103 and $113 million.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AVID and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Real Industry Inc (NASDAQ:RELY)

Real Industry Inc (NASDAQ:RELY) Shares Take Dive

Real Industry Inc (NASDAQ:RELY)

Real Industry Inc (NASDAQ:RELY) stock cratered on Friday, losing over 65% on a volume figure that was almost 90 times the listed daily average. RELY shares gapped down to open at $1 from their Thursday close of $1.70, then went on to make a new 52-week low of $0.25 before closing at $0.65.

Sherman Oaks, CA-based Real Industry Inc (NASDAQ:RELY) is a holding company that seeks to create a sustainably profitable business acquiring companies that meet strict metrics with regards to value and structure. Our business strategy also seeks to take advantage of Real Industry’s U.S. federal net operating loss tax carryforwards of $916 million.

The company, through its subsidiaries, is involved in aluminum melting, processing, recycling, and alloying activities in the United States and internationally. The company operates in two segments, Real Alloy North America and Real Alloy Europe. It processes scrap aluminum and by-products. It manufactures wrought, cast, and specification or foundry alloys. The company serves the automotive, consumer packaging, aerospace, building and construction, steel, and durable goods industries, as well as wrought alloy producers, foundries, and casters.

Real Industry Business

Real Industry Inc (NASDAQ:RELY) reported sales of $1.25 Billion for 2016. However, the company has a market capitalization of less than $20 million. Earnings have been negative since 2012 when the company posted a per share loss of (-$0.34). By 2016, that loss had grown to (-$3.71).

Unfortunately, the earnings losses were not the only headwind experienced by shareholders. In 2014 the company had 13.4 million shares outstanding. In the next two years the company issued more shares, thereby diluting shareholder equity, and by the end of 2016 the number of outstanding shares was listed at 28.72 million.

RELY Stock Performance

In mid-2016, RELY shares were hitting resistance at $9. A steady slide in the share price ensued and by August shares were meeting support around $1.75. Then, On Friday, RELY shares plummeted below the $10 handle. That level is not just important psychologically, the NASDAQ Market has rules that mandate a share’s bid price remain over $12 for a specified amount of time or else the stock could be de-listed.

Year-to-date, RELY stock has lost over 90% of its value. In the past week it has lost 64% of its value. However, the two firms that follow Real Industry Inc (NASDAQ:RELY) rate RELY shares as a “Strong Buy” with a consensus, one-year price target of $5.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RELY and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

EV Energy Partners, L.P. (NASDAQ:EVEP)

EV Energy Partners, L.P. (NASDAQ:EVEP) Stock Booms!

EV Energy Partners, L.P. (NASDAQ:EVEP)

EV Energy Partners, L.P. (NASDAQ:EVEP) shares broke above six-month resistance levels and more than doubled since early September. EVEP stock ended Thursday’s trading session at $0.77 then opened today at $0.78 before rocketing to an inter-day high of $1.16 on heavy volume. EVEP shares have an average trading volume under 200,000 shares but today almost 3 million shares have exchanged hands with 30 minutes left in the trading day.

NASDAQ:EVEP

EV Energy Partners, L.P. (NASDAQ:EVEP), based in Houston, TX, specializes in the acquisition, operation, and development of onshore oil and gas properties in the USA. Operations are currently ongoing at the Barnett Shale, the San Juan Basin, the Appalachian Basin, Michigan, Central Texas, the Monroe Field in Northern Louisiana, the Mid–Continent areas in Oklahoma, Texas, Arkansas, Kansas and Louisiana and the Permian Basin.

EVEP Stock Performance

Between the second week in June and the end of October, EV Energy Partners, L.P. (NASDAQ:EVEP) stock had a trading range between $0.40 and $0.80. The shares had established a new 52-week low in mid-August of $0.37. However in the last seven trading sessions, EVEP stock has gone from $0.60 to today’s high of $1.16.

In 2016, EVEP stock received five ratings downgrades from analysts. Five investment firms follow EV Energy Partners, L.P. (NASDAQ:EVEP). Four rate EVEP shares as a “Hold” and one rates the shares as a “Underperform”. YTD, EVEP has underperformed the sector by around 40%.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EVEP and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Aratana Therapeutics Inc (NASDAQ:PETX) Jumps

Aratana Therapeutics Inc (NASDAQ:PETX)

The market reacted favorably to the earnings release by Aratana Therapeutics Inc (NASDAQ:PETX) and it shares have risen over 18% on heavy volume. After the market closed yesterday, the pet therapeutics company reported total net revenues of $6.2 million and a net loss of (-$8.9) million or (-$0.21) diluted loss per share. According to Zacks Investment Research, analysts were expecting a per share loss of (-$0.26).

Aratana Therapeutics Inc (NASDAQ:PETX)

Founded in 2010, Aratana Therapeutics Inc (NASDAQ:PETX) has its headquarters in Leawood, Kansas. Aratana is a pet therapeutics company that licenses, develops and commercializes therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics, and therapeutic candidates in development, consisting of small molecule pharmaceuticals and biologics.

Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to dogs and cats in a capital and time efficient manner. Aratana’s pipeline includes therapeutic candidates for the potential treatment of pain, inappetence, viral diseases, allergy, cancer and other serious medical conditions.

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics Inc (NASDAQ:PETX) commented on the earnings results, “With the launch of NOCITA, GALLIPRANT and now ENTYCE, Aratana is well-positioned to extend the relationships we have been building within specialty and general practice veterinary clinics over the past year. Aratana continues to remain focused on developing and commercializing innovative pet therapeutics, which we believe is the most underserved and attractive segment of the animal health market.”

PETX Q3 Earnings

The company’s Q3 net loss was (-$8.9) million or (-$0.21) diluted loss per share compared to net loss of (-$13.4) million or (-$0.38) diluted loss per share for the same quarter last year. Aratana recorded $6.2 million in net revenues for Q3, which primarily includes approximately $4.0 million of product sales and $2.2 million in GALLIPRANT licensing and collaboration revenue.

Q3 research and development expenses totaled $3.2 million in comparison to $5.3 million for Q3 2016. Selling, general and administrative expenses totaled $6.9 million in the third quarter ended September 30, 2017 and $21.3 million for the nine-month period ended September 30, 2017.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PETX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Insignia Systems, Inc. (NASDAQ:ISIG) Explodes on Earnings Surprise

Insignia Systems, Inc. (NASDAQ:ISIG)

Insignia Systems, Inc. (NASDAQ:ISIG) stock was up over 80% in morning trading after the company released their Q3 earnings yesterday after the market closed. The global consumer marketing firm reported increases in Net Sales, Gross Profit, and Net Income.

ISIG stock closed yesterday at $1.36, then gapped up to open at $1.58 before hitting the inter-day high of $2.19. While ISIG shares are down year-to-date, and for the past year, they are up over 35% during the past quarter.

Insignia Systems, Inc. (NASDAQ:ISIG)

Q3 Earnings

Net sales increased 19.4% to $7,723,000 in Q3 2017, from $6,469,000 in Q3 2016, primarily due to a 30.4% increase in the number of signs placed. Gross profit in Q3 2017 increased to $2,743,000, or 35.5% of net sales, from $2,000,000, or 30.9% of net sales, in Q3 2016. The increased gross profit was primarily due to an increase in sales and a decrease in cost of services due to the discontinued sale of The Like Machine. Gross profit is highly dependent on sales levels due to the relatively fixed nature of a portion of Insignia’s payments to retailers. Net income for Q3 2017 was $451,000, or $0.04 per basic and diluted share, compared to a net loss of -$167,000, or (-$0.01) per basic and diluted share, for the same period last year.

Insignia Systems, Inc. (NASDAQ:ISIG) President and CEO Kristine Glancy commented, “We are pleased with our quarterly results, having delivered both top and bottom line growth. The quarterly results reflect the continued progress against our strategic initiatives with the addition of new CPG customers, strengthening the relationships with existing clients, and gaining traction on business development projects. These strategic initiatives are expected to positively impact the remainder of 2017 and beyond.”

ISIG Stock

The consensus, one-year price target for ISIG stock is $3.00. Insignia Systems, Inc. (NASDAQ:ISIG) reported a per share loss for 2016 of (-$0.11) on sales of $24.9 million. However, it appears that management has set the course for a more profitable 2017.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ISIG and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Second Sight Medical Products Inc (NASDAQ:EYES),

Good News for Second Sight Medical Products Inc (NASDAQ:EYES)

Second Sight Medical Products Inc (NASDAQ:EYES)

Shares of Second Sight Medical Products Inc (NASDAQ:EYES), headquartered in Sylmar, CA, are up over 10% in late trading on the back of a ten-fold volume increase. The strong move upwards was a result of investor reaction to the consent of the U.S. Food and Drug Administration (FDA) to begin the Orion™ Cortical Visual Prosthesis System (Orion) feasibility clinical study. The approval allows two U.S. sites, the University of California at Los Angeles (UCLA) and Baylor College of Medicine (Baylor) in Houston, to enroll up to five total patients.

Second Sight Medical Products Inc (NASDAQ:EYES),

Second Sight Medical Products Inc (NASDAQ:EYES)’s develops, manufactures, and markets innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. Second Sight’s Orion™ Visual Cortical Prosthesis is being developed to restore some vision to individuals who are blind due to causes other than preventable or treatable conditions.

Will McGuire, President and CEO of Second Sight stated ““We remain on track toward achieving our stated goal of implanting our first Orion patient before year end, and the potential opportunity to provide useful vision to millions of blind individuals worldwide who have no other option today,”

EYES Stock Performance

Despite the science fiction nature of their product that could change the lives of millions of blind people, current financial results have been poor for shareholders. In late 2015, EYES stock was trading above $7, but a lack of profits has seen a downward trend for the shares. In February of 2017, EYES stock briefly rose near $3, but during most of the past year has had the stock below the $2 level.

EYES stock is down 55% for the year, and down 4% for the past month. There is a moderate short position on the company – over 10% of the share’s float is held as a short position.

HC Wainwright covers Second Sight Medical Products Inc (NASDAQ:EYES) and assigns EYES stock a “Strong Buy”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EYES and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Continues Move Higher

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) shares are up 31%, to $7.36, on news of a research collaboration and license agreement with Boehringer Ingelheim to discover and develop novel GalXC™ RNAi therapeutics for the treatment of chronic liver diseases. Under the terms of the agreement, Dicerna may receive more than $200 million in upfront, development and commercial milestone payments, and research and development reimbursement for a GalXC candidate product addressing an undisclosed NASH target. Dicerna is also eligible to receive royalties staggered up to double-digits on worldwide net sales.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), based in Cambridge, MA, discovers and develops RNAi-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where there are recognized connections between the target gene and diseases.

Dicerna’s GalXC technology platform uses RNAi to inhibit the expression of disease-causing genes by destroying the messenger RNAs (mRNAs) of those genes. This new approach has the potential to treat diseases by silencing previously inaccessible drug targets.

Douglas M. Fambrough, President and Chief Executive Officer of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) stated, “With strong capabilities in drug discovery, deep expertise in the cardiometabolic space, and proven commercial experience, Boehringer Ingelheim is a natural partner to speed the development of the first GalXC RNAi program targeting chronic liver disease. The collaboration combines the strong capabilities of both companies to pursue the full potential of Dicerna’s GalXC technology to bring valuable and differentiated RNAi therapies to patients with liver diseases and their healthcare teams, and reflects both the promise of the GalXC technology and the strength of its underlying intellectual property.”

DRNA Stock Performance

Five investment firms follow Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Four rate DRNA shares as a “Strong Buy” and one rates the shares as a “Hold”.

In 2016, DRNA shareholders saw a per share loss of (-$2.87) on total sales of just $300,000. Despite those numbers, shareholders have seen a year-to-date gain of over 95%. Today’s price action (currently at $7.36) eclipses the previous 52-week high of $6.75 and also tops analyst’s consensus one-year price target of $5.75.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DRNA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.